Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions

被引：5

作者：

Ridruejo, Ezequiel ^{[1
]}

Pereson, Matias Javier ^{[2
]}

Flichman, Diego M. ^{[3
]}

Di Lello, Federico Alejandro ^{[2
]}

机构：

[1] Ctr Educ Medica & Invest Clin Norberto Quirno CEM, Hepatol Sect, Dept Med, C1425AS, Unspecified, Argentina

[2] Univ Buenos Aires, Inst Invest Bacteriol & Virol Mol IBaViM, Fac Farm & Bioquim, Junin 9564 Piso, RA-1113 Buenos Aires, DF, Argentina

[3] Univ Buenos Aires, Inst Invest Biomed Retrovirus Sindrome Inmunodefc, RA-1113 Buenos Aires, DF, Argentina

来源：

WORLD JOURNAL OF HEPATOLOGY | 2021年 / 13卷 / 09期

关键词：

Hepatitis C virus; Treatment failure; Resistance; Direct-acting antiviral; SUSTAINED VIROLOGICAL RESPONSE; ANTIVIRAL TREATMENT EFFICACY; INTERFERON PLUS RIBAVIRIN; HIV-INFECTED PATIENTS; PEGYLATED INTERFERON; GENOTYPE; PREVALENCE; NS5A; GRAZOPREVIR; ELBASVIR;

D O I：

10.4254/wjh.v13.i9.1069

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has shown a high rate (> 95%) of sustained virological response even when high baseline RAS prevalence has been reported. In the context of RAS emergence and high rates of sustained viral response, the clinical relevance of variants harboring RAS is still controversial. Therefore, in order to summarize the data available in international guidelines, we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.</p>

引用

页码：1069 / 1078

页数：11

共 61 条

[1] Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [J].

Ghany M.G. ;

Morgan T.R. .

HEPATOLOGY, 2020, 71 (02) :686-721

[2] Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort [J].

Belen Perez, Ana ;

Chueca, Natalia ;

Macias, Juan ;

Antonio Pineda, Juan ;

Salmeron, Javier ;

Rivero-Juarez, Antonio ;

Hidalgo-Tenorio, Carmen ;

Dolores Espinosa, Maria ;

Tellez, Francisco ;

Angel Von-Wichmann, Miguel ;

Omar, Mohamed ;

Santos, Jesus ;

Hernandez-Quero, Jose ;

Joaquin Anton, Jose ;

Collado, Antonio ;

Belen Lozano, Ana ;

Garcia-Deltoro, Miguel ;

Casado, Marta ;

Manuel Pascasio, Juan ;

Selfa, Aida ;

Miguel Rosales, Jose ;

De la Iglesia, Alberto ;

Ignacio Arenas, Juan ;

Garcia-Bujalance, Silvia ;

Jose Rios, Maria ;

Bernal, Enrique ;

Martinez, Onofre ;

Garcia-Herola, Antonio ;

Velez, Monica ;

Rincon, Pilar ;

Garcia, Federico .

PLOS ONE, 2019, 14 (08)

[3] Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients [J].

Belperio, Pamela S. ;

Shahoumian, Troy A. ;

Loomis, Timothy P. ;

Backus, Lisa I. .

JOURNAL OF VIRAL HEPATITIS, 2019, 26 (08) :980-990

[4] Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy [J].

Bertoli, Ada ;

Sorbo, Maria Chiara ;

Aragri, Marianna ;

Lenci, Ilaria ;

Teti, Elisabetta ;

Polilli, Ennio ;

Di Maio, Velia Chiara ;

Gianserra, Laura ;

Biliotti, Elisa ;

Masetti, Chiara ;

Magni, Carlo F. ;

Babudieri, Sergio ;

Nicolini, Laura A. ;

Milana, Martina ;

Cacciatore, Pierluigi ;

Sarmati, Loredana ;

Pellicelli, Adriano ;

Paolucci, Stefania ;

Craxi, Antonio ;

Morisco, Filomena ;

Palitti, Valeria Pace ;

Siciliano, Massimo ;

Coppola, Nicola ;

Iapadre, Nerio ;

Puoti, Massimo ;

Rizzardini, Giuliano ;

Taliani, Gloria ;

Pasquazzi, Caterina ;

Andreoni, Massimo ;

Parruti, Giustino ;

Angelico, Mario ;

Perno, Carlo Federico ;

Cento, Valeria ;

Ceccherini-Silberstein, Francesca .

SCIENTIFIC REPORTS, 2018, 8

[5] Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection [J].

Bourliere, M. ;

Gordon, S. C. ;

Flamm, S. L. ;

Cooper, C. L. ;

Ramji, A. ;

Tong, M. ;

Ravendhran, N. ;

Vierling, J. M. ;

Tran, T. T. ;

Pianko, S. ;

Bansal, M. B. ;

Ledinghen, V. de ;

Hyland, R. H. ;

Stamm, L. M. ;

Dvory-Sobol, H. ;

Svarovskaia, E. ;

Zhang, J. ;

Huang, K. C. ;

Subramanian, G. M. ;

Brainard, D. M. ;

McHutchison, J. G. ;

Verna, E. C. ;

Buggisch, P. ;

Landis, C. S. ;

Younes, Z. H. ;

Curry, M. P. ;

Strasser, S. I. ;

Schiff, E. R. ;

Reddy, K. R. ;

Manns, M. P. ;

Kowdley, K. V. ;

Zeuzem, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22) :2134-2146

[6] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].

Carrat, F ;

Bani-Sadr, F ;

Pol, S ;

Rosenthal, E ;

Lunel-Fabiani, F ;

Benzekri, A ;

Morand, P ;

Goujard, C ;

Pialoux, G ;

Piroth, L ;

Salmon-Céron, D ;

Degott, C ;

Cacoub, P ;

Perronne, C .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848

[7] Global prevalence of pre-existing HCV variants resistant to directacting antiviral agents (DAAs): mining the GenBank HCV genome data [J].

Chen, Zhi-wei ;

Li, Hu ;

Ren, Hong ;

Hu, Peng .

SCIENTIFIC REPORTS, 2016, 6

[8] Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice [J].

Chevaliez, Stephane ;

Bouvier-Alias, Magali ;

Brillet, Rozenn ;

Pawlotsky, Jean-Michel .

PLOS ONE, 2009, 4 (12) :1-9

[9] Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C [J].

Childs, Kate ;

Davis, Christopher ;

Cannon, Mary ;

Montague, Sarah ;

Filipe, Ana ;

Tong, Lily ;

Simmonds, Peter ;

Smith, Donald ;

Thomson, Emma C. ;

Dusheiko, Geoff ;

Agarwal, Kosh .

JOURNAL OF HEPATOLOGY, 2019, 71 (06) :1099-1105

[10] Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus [J].

Da, Ben L. ;

Lourdusamy, Vennis ;

Kushner, Tatyana ;

Dieterich, Douglas ;

Saberi, Behnam .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (06) :859-861

← 1 2 3 4 5 6 7 →